The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 19, 2019

Filed:

Nov. 17, 2017
Applicant:

Cydex Pharmaceuticals, Inc., San Diego, CA (US);

Inventors:

James D. Pipkin, Lawrence, KS (US);

Rupert O. Zimmerer, Lawrence, KS (US);

Diane O. Thompson, Overland Park, KS (US);

Gerold L. Mosher, Kansas City, MO (US);

Assignee:

CyDex Pharmaceuticals, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); B82Y 5/00 (2011.01); C08L 5/16 (2006.01); A61K 31/58 (2006.01); A61K 45/06 (2006.01); A61K 47/40 (2006.01); A61K 47/61 (2017.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); C08B 37/16 (2006.01); A61K 31/573 (2006.01); A61K 31/724 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6851 (2017.08); A61K 9/0078 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 31/724 (2013.01); A61K 45/06 (2013.01); A61K 47/40 (2013.01); A61K 47/61 (2017.08); A61K 47/6951 (2017.08); B82Y 5/00 (2013.01); C08B 37/0015 (2013.01); C08L 5/16 (2013.01);
Abstract

An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.


Find Patent Forward Citations

Loading…